Atopic Clinical Trials in Toronto, Ontario
9 recruitingToronto, Ontario, Canada
Showing 1–9 of 9 trials
Recruiting
Phase 2
A Study of KT-621 Administered Orally to Participants With Moderate to Severe Atopic Dermatitis
Atopic Dermatitis
Kymera Therapeutics, Inc.200 enrolled67 locationsNCT07217015
Recruiting
Phase 2
A Phase 2b Study of the Effects of Camoteskimab in Adults With Moderate-to-Severe Atopic Dermatitis
DermatitisAtopic DermatitisEczema Atopic Dermatitis+5 more
Apollo Therapeutics Ltd280 enrolled85 locationsNCT07599813
Recruiting
Phase 2
A Long-term Safety and Efficacy Study Evaluating APG777 in Atopic Dermatitis
Atopic Dermatitis
Apogee Therapeutics, Inc.350 enrolled48 locationsNCT07003425
Recruiting
Phase 3
A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab on Background Topical Corticosteroids Therapy in Participants Aged 12 Years and Older With Moderate-to-severe AD Who Have Had an Inadequate Response to Prior Biologic Therapy or an Oral JAK Inhibitor
Dermatitis Atopic
Sanofi636 enrolled147 locationsNCT06241118
Recruiting
Phase 2
A Study To Learn About Two Study Medicines (PF-07275315 And PF-07264660) In People Who Have Moderate To Severe Atopic Dermatitis
Atopic Dermatitis
Pfizer340 enrolled98 locationsNCT05995964
Recruiting
Phase 2
Open Label, Long-term Study Evaluating Safety and Efficacy of Subcutaneous Amlitelimab in Participants Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis
Dermatitis Atopic
Sanofi901 enrolled175 locationsNCT05769777
Recruiting
Phase 2
Phase 2a Study to Assess the Efficacy,Safety and Tolerability of GIA632 in Adult Participants With Moderate to Severe Atopic Dermatitis
Atopic Dermatitis
Novartis Pharmaceuticals84 enrolled28 locationsNCT07220577
Recruiting
Phase 3
A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis
Atopic Dermatitis
AbbVie675 enrolled148 locationsNCT06461897
Recruiting
Phase 3
A Study to Assess the Efficacy and Safety of Ruxolitinib Cream in Children and Adolescents (6 to <18 Years Old) With Moderate Atopic Dermatitis
Atopic Dermatitis
Incyte Corporation240 enrolled96 locationsNCT06832618